Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
OTLKW was delisted on the 16th of February, 2022.
6 hedge funds and large institutions have $200K invested in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in 2018 Q4 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$53.1K |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$52.5K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$22.4K |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$15.8K |
| 5 |
PC
PointState Capital
New York
|
+$12.6K |
Top Sellers
OTLKW Hedge Fund Activity: Q4 2018 in Review
6 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) for Q4 2018, worth a combined $200K.
Buyers outnumbered sellers: 6 funds opened new OTLKW positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $53.1K.
- 6 institutional investors held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) as of Q4 2018, up from 0 in Q3 2018.
- Funds reported $200K of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 stock for Q4 2018.
- 6 funds opened new Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 positions in Q4 2018 and 0 closed out, a net change of +6 holders.
- The largest Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 buyer in Q4 2018 was Perceptive Advisors, an estimated $53.1K added.
Based on aggregated 13F filings for Q4 2018.